BRPI1015018B1 - Métodos para selecionar oócitos e embriões competentes com alto potencial de êxito de gravidez - Google Patents
Métodos para selecionar oócitos e embriões competentes com alto potencial de êxito de gravidez Download PDFInfo
- Publication number
- BRPI1015018B1 BRPI1015018B1 BRPI1015018-8A BRPI1015018A BRPI1015018B1 BR PI1015018 B1 BRPI1015018 B1 BR PI1015018B1 BR PI1015018 A BRPI1015018 A BR PI1015018A BR PI1015018 B1 BRPI1015018 B1 BR PI1015018B1
- Authority
- BR
- Brazil
- Prior art keywords
- embryo
- pregnancy
- oocyte
- genes
- expression
- Prior art date
Links
- 230000035935 pregnancy Effects 0.000 title claims abstract description 77
- 238000000034 method Methods 0.000 title claims abstract description 59
- 210000002257 embryonic structure Anatomy 0.000 title claims abstract description 37
- 210000000287 oocyte Anatomy 0.000 claims abstract description 83
- 108090000623 proteins and genes Proteins 0.000 claims description 106
- 210000001771 cumulus cell Anatomy 0.000 claims description 91
- 210000001161 mammalian embryo Anatomy 0.000 claims description 84
- 230000014509 gene expression Effects 0.000 claims description 63
- 238000002513 implantation Methods 0.000 claims description 22
- -1 ionotropic Chemical compound 0.000 claims description 15
- 102100022165 Nuclear factor 1 B-type Human genes 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 102100022761 Glutamate receptor ionotropic, kainate 5 Human genes 0.000 claims description 11
- 101000903313 Homo sapiens Glutamate receptor ionotropic, kainate 5 Proteins 0.000 claims description 11
- 101000734572 Homo sapiens Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Proteins 0.000 claims description 11
- 101000983166 Homo sapiens Phospholipase A2 group V Proteins 0.000 claims description 11
- 102100022162 Nuclear factor 1 C-type Human genes 0.000 claims description 11
- 102100034796 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human genes 0.000 claims description 11
- 102100026832 Phospholipase A2 group V Human genes 0.000 claims description 11
- 102100029197 SLAM family member 6 Human genes 0.000 claims description 11
- 102100033561 Calmodulin-binding transcription activator 1 Human genes 0.000 claims description 10
- 230000002018 overexpression Effects 0.000 claims description 10
- 102100021717 Early growth response protein 3 Human genes 0.000 claims description 9
- 102100040861 G0/G1 switch protein 2 Human genes 0.000 claims description 9
- 101000945309 Homo sapiens Calmodulin-binding transcription activator 1 Proteins 0.000 claims description 9
- 101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 claims description 9
- 101000893656 Homo sapiens G0/G1 switch protein 2 Proteins 0.000 claims description 9
- 101000601664 Homo sapiens Paired box protein Pax-8 Proteins 0.000 claims description 8
- 101000800583 Homo sapiens Transcription factor 20 Proteins 0.000 claims description 8
- 102100037502 Paired box protein Pax-8 Human genes 0.000 claims description 8
- 102100022134 Protocadherin Fat 3 Human genes 0.000 claims description 8
- 102100033142 Transcription factor 20 Human genes 0.000 claims description 8
- 210000002503 granulosa cell Anatomy 0.000 claims description 8
- 102100040016 Amyloid-beta A4 precursor protein-binding family B member 3 Human genes 0.000 claims description 7
- 101000959823 Homo sapiens Amyloid-beta A4 precursor protein-binding family B member 3 Proteins 0.000 claims description 7
- 101000875075 Homo sapiens Cannabinoid receptor 2 Proteins 0.000 claims description 7
- 101000941892 Homo sapiens Leucine-rich repeat and calponin homology domain-containing protein 4 Proteins 0.000 claims description 7
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims description 7
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 claims description 7
- 101000855002 Homo sapiens Protein Wnt-6 Proteins 0.000 claims description 7
- 102100040021 Interferon-induced transmembrane protein 1 Human genes 0.000 claims description 7
- 102100032680 Leucine-rich repeat and calponin homology domain-containing protein 4 Human genes 0.000 claims description 7
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims description 7
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 claims description 7
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 claims description 7
- 102100020732 Protein Wnt-6 Human genes 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 claims description 6
- 101000642514 Homo sapiens Transcription factor SOX-4 Proteins 0.000 claims description 6
- 102100020847 Protein FosB Human genes 0.000 claims description 6
- 102100036693 Transcription factor SOX-4 Human genes 0.000 claims description 6
- 210000003754 fetus Anatomy 0.000 claims description 5
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 claims description 4
- 101000863898 Homo sapiens CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 claims description 4
- 101000994496 Homo sapiens cAMP-dependent protein kinase catalytic subunit alpha Proteins 0.000 claims description 4
- 102100028437 Versican core protein Human genes 0.000 claims description 4
- 102100032791 cAMP-dependent protein kinase catalytic subunit alpha Human genes 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 102000021620 Calcium-binding protein 4 Human genes 0.000 claims 5
- 108091012416 Calcium-binding protein 4 Proteins 0.000 claims 5
- 102000004503 Perforin Human genes 0.000 claims 5
- 108010056995 Perforin Proteins 0.000 claims 5
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims 5
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims 5
- 102000004872 neuroligin 2 Human genes 0.000 claims 5
- 108090001075 neuroligin 2 Proteins 0.000 claims 5
- 101710170464 Nuclear factor 1 B-type Proteins 0.000 claims 4
- 101710113455 Nuclear factor 1 C-type Proteins 0.000 claims 4
- 101710083278 SLAM family member 6 Proteins 0.000 claims 4
- 102000037054 SLC-Transporter Human genes 0.000 claims 4
- 108091006207 SLC-Transporter Proteins 0.000 claims 4
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims 3
- 102100036509 Erythropoietin receptor Human genes 0.000 claims 3
- 102000016824 Keratin-associated protein 8-1 Human genes 0.000 claims 3
- 108050006422 Keratin-associated protein 8-1 Proteins 0.000 claims 3
- 101710095095 Protocadherin Fat 3 Proteins 0.000 claims 3
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 claims 2
- 101000974009 Homo sapiens Nitric oxide synthase, brain Proteins 0.000 claims 2
- 102000004157 Hydrolases Human genes 0.000 claims 2
- 108090000604 Hydrolases Proteins 0.000 claims 2
- 101710087399 Interferon-induced transmembrane protein 1 Proteins 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 2
- 101100259224 Oryctolagus cuniculus SYPL2 gene Proteins 0.000 claims 2
- 230000004570 RNA-binding Effects 0.000 claims 2
- 102000004584 Somatomedin Receptors Human genes 0.000 claims 2
- 108010017622 Somatomedin Receptors Proteins 0.000 claims 2
- 101710200894 Versican core protein Proteins 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 102100025580 Calmodulin-1 Human genes 0.000 claims 1
- 101710164735 Calmodulin-1 Proteins 0.000 claims 1
- 101710192426 Calmodulin-binding transcription activator 1 Proteins 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241000713333 Mouse mammary tumor virus Species 0.000 claims 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims 1
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims 1
- 108700015968 Slam family Proteins 0.000 claims 1
- 102000004874 Synaptophysin Human genes 0.000 claims 1
- 108090001076 Synaptophysin Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 102000006783 calponin Human genes 0.000 claims 1
- 108010086826 calponin Proteins 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 230000001057 ionotropic effect Effects 0.000 claims 1
- 150000002891 organic anions Chemical class 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000020509 sex determination Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 description 42
- 108091006687 SLCO1A2 Proteins 0.000 description 27
- 102100032846 Solute carrier organic anion transporter family member 1A2 Human genes 0.000 description 27
- 150000007523 nucleic acids Chemical class 0.000 description 19
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 16
- 230000003321 amplification Effects 0.000 description 15
- 238000003199 nucleic acid amplification method Methods 0.000 description 15
- 238000002493 microarray Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 10
- 230000004720 fertilization Effects 0.000 description 10
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 8
- 101000973211 Homo sapiens Nuclear factor 1 B-type Proteins 0.000 description 8
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 230000000877 morphologic effect Effects 0.000 description 8
- 102100034119 ADP-ribosylhydrolase ARH1 Human genes 0.000 description 7
- 101150095726 CABP4 gene Proteins 0.000 description 7
- 102100030048 Calcium-binding protein 4 Human genes 0.000 description 7
- 102100021194 Glypican-6 Human genes 0.000 description 7
- 101000780532 Homo sapiens ADP-ribosylhydrolase ARH1 Proteins 0.000 description 7
- 101001040704 Homo sapiens Glypican-6 Proteins 0.000 description 7
- 101000973200 Homo sapiens Nuclear factor 1 C-type Proteins 0.000 description 7
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 7
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 7
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 7
- 101000988412 Homo sapiens cGMP-specific 3',5'-cyclic phosphodiesterase Proteins 0.000 description 7
- 102100028467 Perforin-1 Human genes 0.000 description 7
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 7
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 description 6
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 description 6
- 108020004394 Complementary RNA Proteins 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 6
- 239000003184 complementary RNA Substances 0.000 description 6
- 230000013020 embryo development Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 101001034844 Homo sapiens Interferon-induced transmembrane protein 1 Proteins 0.000 description 5
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 description 5
- 101000824415 Homo sapiens Protocadherin Fat 3 Proteins 0.000 description 5
- 101001116931 Homo sapiens Protocadherin alpha-6 Proteins 0.000 description 5
- 101000868391 Homo sapiens Voltage-dependent calcium channel gamma-6 subunit Proteins 0.000 description 5
- 108010008858 Nitric Oxide Synthase Type I Proteins 0.000 description 5
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 5
- 102100024278 Protocadherin alpha-6 Human genes 0.000 description 5
- 108091006699 SLC24A3 Proteins 0.000 description 5
- 108091006976 SLC40A1 Proteins 0.000 description 5
- 108091006279 SLC5A12 Proteins 0.000 description 5
- 102100037203 Sodium-coupled monocarboxylate transporter 2 Human genes 0.000 description 5
- 102100032070 Sodium/potassium/calcium exchanger 3 Human genes 0.000 description 5
- 102100032008 Solute carrier family 40 member 1 Human genes 0.000 description 5
- 102100032335 Voltage-dependent calcium channel gamma-8 subunit Human genes 0.000 description 5
- 210000001109 blastomere Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000007466 Male Infertility Diseases 0.000 description 4
- 208000034702 Multiple pregnancies Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 108091006269 SLC5A2 Proteins 0.000 description 3
- 102100020888 Sodium/glucose cotransporter 2 Human genes 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000011049 pearl Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102100038778 Amphiregulin Human genes 0.000 description 2
- 108010033760 Amphiregulin Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 102100028906 Catenin delta-1 Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000006312 Cyclin D2 Human genes 0.000 description 2
- 108010058544 Cyclin D2 Proteins 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000001162 G-test Methods 0.000 description 2
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 2
- 101710119049 Glutathione peroxidase 3 Proteins 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
- 102100038367 Gremlin-1 Human genes 0.000 description 2
- 101710169781 Gremlin-1 Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000603173 Homo sapiens Neuroligin-2 Proteins 0.000 description 2
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 2
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 2
- 101710197056 Hyaluronan synthase 2 Proteins 0.000 description 2
- 102100040206 Hyaluronan synthase 2 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100038939 Neuroligin-2 Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 2
- 101150029664 PELO gene Proteins 0.000 description 2
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000034790 Twin pregnancy Diseases 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 108010031971 delta catenin Proteins 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000032686 female pregnancy Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 240000005369 Alstonia scholaris Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108700024832 B-Cell CLL-Lymphoma 10 Proteins 0.000 description 1
- 102100037598 B-cell lymphoma/leukemia 10 Human genes 0.000 description 1
- 101150074953 BCL10 gene Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102100038713 Death domain-containing protein CRADD Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 102100030540 Gap junction alpha-5 protein Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000957914 Homo sapiens Death domain-containing protein CRADD Proteins 0.000 description 1
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 1
- 101000726548 Homo sapiens Gap junction alpha-5 protein Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001019602 Homo sapiens Interleukin-17 receptor C Proteins 0.000 description 1
- 101000957259 Homo sapiens Mitotic spindle assembly checkpoint protein MAD2A Proteins 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101100041816 Homo sapiens SCD gene Proteins 0.000 description 1
- 101000836079 Homo sapiens Serpin B8 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000637726 Homo sapiens Toll/interleukin-1 receptor domain-containing adapter protein Proteins 0.000 description 1
- 101000830600 Homo sapiens Tumor necrosis factor ligand superfamily member 13 Proteins 0.000 description 1
- 238000003744 In vitro fertilisation Methods 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 102000049772 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102100035012 Interleukin-17 receptor C Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010057021 Menotropins Proteins 0.000 description 1
- 102100038792 Mitotic spindle assembly checkpoint protein MAD2A Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150097713 SCD1 gene Proteins 0.000 description 1
- 102100025520 Serpin B8 Human genes 0.000 description 1
- 102100028897 Stearoyl-CoA desaturase Human genes 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 102100032120 Toll/interleukin-1 receptor domain-containing adapter protein Human genes 0.000 description 1
- 102100024585 Tumor necrosis factor ligand superfamily member 13 Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008777 canonical pathway Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013079 data visualisation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000028801 embryonic cleavage Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001733 follicular fluid Anatomy 0.000 description 1
- 108010081934 follitropin beta Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000001667 gestational sac Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940032750 menopur Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000365 steroidogenetic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000022814 xenobiotic metabolic process Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Tabela A: grupo de genes preditivos.
- i) fornecer ao referido indivíduo do sexo feminino pelo menos um oócito com suas células do cumulus;
- ii) determinar por um método da invenção se o referido oócito é um oócito competente.
- i) isolar da referida mulher pelo menos um oócito com suas células do cumulus sob ciclos naturais, modificados ou estimulados;
- ii) determinar por um método da invenção se o referido oócito é um oócito competente;
- iii) e monitorar a eficácia do tratamento COS baseado se ele resulta em um oócito competente.
- i) prover um oócito com suas células do cumulus
- ii) fertilizar dito oócito in vitro
- iii) determinar se o embrião que resulta da etapa ii) é competente determinando-se, por um método da invenção, se dito oócito da etapa i) é um oócito competente.
- i) selecionar um embrião competente pela realização de um método da invenção
- ii) implantar o embrião selecionado na etapa i) no útero de dita fêmea.
Tabela 1: As características das amostras de células do cumulus neste estudoCC: células do cumulus, P+: células do cumulus de embriões com resultado positivo de gravidez, P-: células do cumulus de embriões sem resultado de gravidez, G1/2: células do cumulus de embriões dos graus 1-2, G3/4: células do cumulus de embriões dos graus 3-4, NT: sem transferência.
Tabela B: Grupo de genes preditivos
Claims (3)
- Método para selecionar um oócito ou um embrião caracterizado pelo fato de compreender as etapas de:
a) medir, em uma célula do cumulus adjacente ao referido oócito ou ao referido embrião, o nível de expressão dos genes dos grupos A, B e C, em que:- - o grupo A consiste em fosfoenolpiruvatocarboxiquinase 1 (PCK-1), ADP-ribosilarginina hidrolase (ADPRH), proteína de ligação a cálcio 4 (CABP4), Membro 6 da família SLAM (SLAMF6), Ativador de transcrição de ligação à calmodulina 1 (CAMTA1), Proteoglicana 2 de condroitina sulfato (CSPG2) e Perforina 1 (PRF1);
- - o grupo B consiste em Homólogo B do oncogene viral de osteosarcoma murino FBJ (FOSB), Neuroligina 2 (NLGN2), Fosfodiesterase 5A, cGMP-específica (PDE5A), Fosfolipase A2, grupo V (PLA2G5), Glipican 6 (GPC6) e Resposta de crescimento inicial 3 (EGR3); e
- - o grupo C consiste em Fator nuclear I/B (NFIB), Fator nuclear I/C (NFIC), Receptor de fator de crescimento insulina-like 1 (IGF1R), G0/G1 comutador 2 (G0S2), Receptor de glutamato, ionotrópico, cainato 5 (GRIK5) e Motivo de ligação de RNA, proteína de interação de fita simples 1 (RBMS1);
b) comparar o nível de expressão medido na etapa a) com o nível de expressão dos referentes genes medidos nas células da granulosa;
c) selecionar embriões com uma alta taxa de implantação levando à gravidez ou de oócitos que quando fertilizados produzirão um embrião viável com uma elevada taxa de implantação levando à gravidez; em que- - a super expressão de um ou mais genes selecionados do grupo A é preditivo de um embrião com uma elevada taxa de implantação levando à gravidez ou de um oócito que quando fertilizado produz um embrião viável com uma elevada taxa de implantação levando à gravidez;
- - a super expressão de um ou mais genes selecionados do grupo B é preditivo de um embrião que não possui uma elevada taxa de implantação levando à gravidez ou de um oócito que quando fertilizado não produz um embrião viável com uma elevada taxa de implantação levando à gravidez, em que o embrião não é capaz de implantação;
- - a super expressão de um ou mais genes selecionados do grupo C é preditivo de um embrião que não possui uma elevada taxa de implantação levando à gravidez ou de um oócito que quando fertilizado não produz um embrião viável com uma elevada taxa de implantação levando à gravidez devido à inibição precoce do crescimento do embrião.
- Método para selecionar um oócito caracterizado pelo fato de compreender as etapas de:
- a) medir o nível de expressão de 45 genes em uma célula do cumulus adjacente ao referido oócito, onde os referidos 45 genes são Membro 6 da família do sítio de integração MMTV tipo sem alça (WNT6), Domínio contendo repetições ricas em leucina e homologia à calponina (CH) LRCH4), box pareado 8 (PAX8), Proteína de ligação de cálcio 4 (CABP4), fosfodiesterase 5A, cGMP-específica (PDE5A), BCL2-tipo 11 (facilitador de apoptose) (BCL2L11), fosfoenolpiruvato carboxiquinase 1 (PCK1), Fator de transcrição 20 (AR1) (TCF20), Membro 6 da família SLAM (SLAMF6), receptor de eritropoietina (EPOR), Subunidade gama 6 do canal de cálcio dependente de voltagem (CACNG6), Domínio 1 contendo pirina da família NLR (NLRP1), Molécula de adesão celular a plaqueta/endotélio (PECAM1), Óxido nítrico sintase 1 (NOS1), Fator de ativação de transcrição 3 (ATF3), Proteína associada à queratina 8-1 (KRTAP8), Receptor de glutamato, ionotrópico, cainato 5 (GRIK5), Membro 3 da família de carreador de soluto 24 (SLC24A3), Membro 12 da família de carreador de soluto 5 (SLC5A12), Membro 2 da família de carreador de soluto 10 (SLCA10A2), Membro 1A2 da família de transportador de ânions orgânicos carreadores de soluto (SLCO1A2), Membro 5 da família de carreador de soluto 25 (SLC25A5), Sinaptofisina tipo 2 (MG29), Neuroligina 2 (NLGN2), Proteína quinase, dependente de cAMP, catalítica, alfa (PRKACA), Homólogo B do oncogene viral de osteosarcoma murino FBJ (FOSB), ST3 beta-galactosida alfa-2,3-sialil transferase 3 (SIAT6), Lisil oxidase tipo 2 (LOXL2), Perforina 1 (PRF1), ADP-ribosilarginina hidrolase (ADPRH), Membro 3, família B da proteína de ligação ao precursor beta-amilóide (A4) (APBB3), Resposta de crescimento inicial 3 (EGR3), Receptor de canabinóide 2 (macrófago) (CNR2), Proteína 1 transmembrana induzida por interferon (IFITM1), Fosfolipase A2, grupo V (PLA2G5), Ativador de transcrição de ligação à calmodulina 1 (CAMTA1), SRY (região de determinação de sexo Y)-box 4 (SOX4), Fator nuclear I/B (NFIB), Fator nuclear I/C (NFIC), Motivo de ligação de RNA, proteína de interação de fita simples 1(RBMS1), G0/G1 comutador 2 (G0S2), Homólogo 3 supressor de tumor FAT (FAT3), Membro 1 da família de carreador de soluto 40 (SLC40A1), glipican 6 (GPC6) e Receptor de fator de crescimento insulina-like 1 (IGF1R);
- b) comparar o referido nível de expressão medido na etapa a) com aquele medido em um controle, em que o referido controle é uma célula cumulus adjacente a um oócito que, uma vez fertilizado, produziu um embrião viável associado com uma elevada taxa de implantação levando à gravidez; e
- c) concluir que o referido oócito, uma vez fertilizado não irá produzir um embrião viável associado com uma elevada taxa de implantação levando à gravidez, se uma expressão diferencial entre o referido oócito e o referido controle é medida na etapa b), e selecionar oócitos que possuem o nível de expressão medido em a) estatisticamente similar ao nível de expressão observado no controle como sendo oócitos que quando fertilizados produzirão embriões viáveis associados com uma elevada taxa de implantação levando à gravidez.
- Método para selecionar embriões caracterizado pelo fato de compreender as etapas de:
- a) medir o nível de expressão de 45 genes em uma célula do cumulus adjacente ao embrião, onde os referidos 45 genes são WNT6, LRCH4, PAX8, CABP4, PDE5A, BCL2L11, PCK1, TCF20, SLAMF6, EPOR, CACNG6, NLRP1, PECAM1, NOSI, ATF3, KRTAP8, GRIK5, SLC24A3, SLC5A12, SLCA10A2, SLCO1A2, SLC25A5, MG29, NLGN2, PRKACA, FOSB, SIAT6, LOXL2, PRF1, ADPRH, APBB3, EGR3, CNR2, IFITM1, PLA2G5, CAMTA1, SOX4, NFIB, NFIC, RBMS1, G0S2, FAT3, SLC40A1, GPC6 e IGF1R;
- b) comparar o referido nível de expressão medido na etapa a) com aquele medido em um controle, em que o referido controle é uma célula cumulus adjacente a um embrião que deu origem a um feto viável; e
- c) concluir que o referido embrião não dará origem a um feto viável se uma expressão diferencial entre o referido oócito e o referido controle é medida na etapa b), e selecionar embriões que possuem o nível de expressão medido em a) estatisticamente similar ao nível de expressão observado no controle como sendo oócitos com uma elevada taxa de implantação levando à gravidez.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09305331.2 | 2009-04-17 | ||
EP09305331 | 2009-04-17 | ||
US17550309P | 2009-05-05 | 2009-05-05 | |
US61/175,503 | 2009-05-05 | ||
PCT/EP2010/054714 WO2010118991A1 (en) | 2009-04-17 | 2010-04-09 | Methods for selecting oocytes and competent embryos with high potential for pregnancy outcome |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI1015018A2 BRPI1015018A2 (pt) | 2016-04-12 |
BRPI1015018B1 true BRPI1015018B1 (pt) | 2021-04-06 |
BRPI1015018B8 BRPI1015018B8 (pt) | 2021-06-15 |
Family
ID=40984880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1015018A BRPI1015018B8 (pt) | 2009-04-17 | 2010-04-09 | métodos para selecionar oócitos e embriões competentes com alto potencial de êxito de gravidez |
Country Status (11)
Country | Link |
---|---|
US (2) | US8754014B2 (pt) |
EP (2) | EP3037554B1 (pt) |
JP (1) | JP5828143B2 (pt) |
CN (1) | CN102459635B (pt) |
AU (1) | AU2010237203B2 (pt) |
BR (1) | BRPI1015018B8 (pt) |
CA (1) | CA2758351C (pt) |
ES (2) | ES2572830T3 (pt) |
IL (1) | IL215662A0 (pt) |
TR (1) | TR201815478T4 (pt) |
WO (1) | WO2010118991A1 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2499261A4 (en) * | 2009-11-10 | 2013-05-15 | Gema Diagnostics Inc | GENES EXPRESSED DIFFERENTIALLY BY CUMULUS CELLS AND ASSAYS USING THEM TO IDENTIFY COMPETENT OCYTES FOR PREGNANCY |
US20130231263A1 (en) * | 2010-10-18 | 2013-09-05 | Institut National De La Sante Et De La Recherche M | Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome |
ES2663134T3 (es) | 2010-11-24 | 2018-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Métodos de selección de ovocitos competentes y embriones competentes con un alto potencial para un resultado de embarazo |
WO2012109326A2 (en) * | 2011-02-09 | 2012-08-16 | Temple University-Of The Commonwealth System Of Higher Education | Determination of oocyte quality |
JP6186353B2 (ja) | 2011-07-01 | 2017-08-23 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ヒト卵丘細胞の発生ステージを決定するための方法 |
WO2013056002A1 (en) * | 2011-10-12 | 2013-04-18 | University Of Iowa Research Foundation | Use of microrna for assessing embryos grown in vitro and improving culture media |
US20140296104A1 (en) * | 2011-10-14 | 2014-10-02 | Gema Diagnostics, Inc. | Genes Differentially Expressed by Cumulus Cells and Assays Using Same to Identify Pregnancy Competent Oocytes |
US20140206930A1 (en) * | 2013-01-18 | 2014-07-24 | Inguran, Llc | Twinning with sex sorted sperm |
CN104450904A (zh) * | 2014-12-02 | 2015-03-25 | 柳州市妇幼保健院 | 利用颗粒细胞端粒长度来判断胚胎发育潜能的方法 |
CN104561309B (zh) * | 2015-01-04 | 2017-04-19 | 北京积水潭医院 | 一种来自人辅助生殖囊胚植入前进行出生安全性预测的试剂盒 |
CN104561311B (zh) * | 2015-01-04 | 2016-08-17 | 北京大学第三医院 | 一种来自人辅助生殖胚胎发育早期出生安全性预测的试剂盒 |
WO2017042309A1 (en) * | 2015-09-11 | 2017-03-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Non-invasive methods for assessing genetic integrity of pluripotent stem cells |
RU2625777C1 (ru) * | 2016-04-11 | 2017-07-18 | Илья Викторович Сенечкин | Способ определения in vitro перспективных эмбрионов для последующей имплантации в матку при проведении процедуры экстракорпорального оплодотворения (эко) |
CA3020437A1 (en) | 2016-04-29 | 2017-11-02 | Innovation Hammer Llc | Formulations and methods for treating photosynthetic organisms and enhancing qualities and quantities of yields with glycan composite formulations |
CN105886655A (zh) * | 2016-06-24 | 2016-08-24 | 天津市畜牧兽医研究所 | 一种检测猪nlrp6的核苷酸序列及应用 |
JP6732722B2 (ja) * | 2017-12-11 | 2020-08-05 | 憲隆 福永 | 胚選抜システム |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
US7229946B2 (en) | 2003-03-24 | 2007-06-12 | Saudi Basic Industries Corporation | Catalyst composition for the selective conversion of alkanes to unsaturated carboxylic acids, method of making and method of using thereof |
WO2005094306A2 (en) * | 2004-03-29 | 2005-10-13 | Michigan State University | Identification of genes or polypeptides the expression of which correlates to fertility, ovarian function and/or fetal/newborn viability |
-
2010
- 2010-04-09 TR TR2018/15478T patent/TR201815478T4/tr unknown
- 2010-04-09 JP JP2012505130A patent/JP5828143B2/ja active Active
- 2010-04-09 EP EP16151156.3A patent/EP3037554B1/en active Active
- 2010-04-09 AU AU2010237203A patent/AU2010237203B2/en not_active Ceased
- 2010-04-09 BR BRPI1015018A patent/BRPI1015018B8/pt not_active IP Right Cessation
- 2010-04-09 CN CN201080025898.8A patent/CN102459635B/zh not_active Expired - Fee Related
- 2010-04-09 WO PCT/EP2010/054714 patent/WO2010118991A1/en active Application Filing
- 2010-04-09 ES ES10713218.5T patent/ES2572830T3/es active Active
- 2010-04-09 EP EP10713218.5A patent/EP2419526B1/en active Active
- 2010-04-09 US US13/264,589 patent/US8754014B2/en active Active
- 2010-04-09 ES ES16151156.3T patent/ES2690453T3/es active Active
- 2010-04-09 CA CA2758351A patent/CA2758351C/en active Active
-
2011
- 2011-10-10 IL IL215662A patent/IL215662A0/en active IP Right Grant
-
2014
- 2014-01-30 US US14/168,052 patent/US20140148363A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US8754014B2 (en) | 2014-06-17 |
CA2758351C (en) | 2018-11-20 |
BRPI1015018A2 (pt) | 2016-04-12 |
JP5828143B2 (ja) | 2015-12-02 |
EP3037554B1 (en) | 2018-08-01 |
AU2010237203B2 (en) | 2013-08-01 |
WO2010118991A1 (en) | 2010-10-21 |
US20140148363A1 (en) | 2014-05-29 |
ES2690453T3 (es) | 2018-11-21 |
BRPI1015018B8 (pt) | 2021-06-15 |
CN102459635A (zh) | 2012-05-16 |
EP2419526A1 (en) | 2012-02-22 |
EP3037554A1 (en) | 2016-06-29 |
US20120077697A1 (en) | 2012-03-29 |
EP2419526B1 (en) | 2016-03-30 |
CN102459635B (zh) | 2015-07-29 |
AU2010237203A1 (en) | 2011-11-10 |
ES2572830T3 (es) | 2016-06-02 |
CA2758351A1 (en) | 2010-10-21 |
JP2012523826A (ja) | 2012-10-11 |
TR201815478T4 (tr) | 2018-11-21 |
IL215662A0 (en) | 2012-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8754014B2 (en) | Methods for selecting oocytes and competent embryos with high potential for pregnancy outcome | |
US9090938B2 (en) | Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome | |
JP2015527870A (ja) | 推定出生児が状態を発症する危険性を評価するための方法およびデバイス | |
MX2007009562A (es) | Identificacion de marcadores de diagnostico moleculares para endometriosis en linfocitos sanguineos. | |
EP2480883B1 (en) | Methods for assessing infertility and/or egg quality | |
US20140171337A1 (en) | Methods and devices for assessing risk of female infertility | |
CA2842839A1 (en) | Ovarian markers of follicular maturity and uses thereof | |
JP2013510575A (ja) | 卵丘細胞が差示発現する遺伝子およびそれらを用いる妊娠受容能をもつ卵母細胞の同定のためのアッセイ | |
ES2886472T3 (es) | Métodos para la determinación de la etapa de desarrollo de células del cúmulo humanas | |
WO2013056258A1 (en) | Genes differentially expressed by cumulus cells and assays using same to identify pregnancy competent oocytes | |
Class et al. | Patent application title: METHODS FOR SELECTING COMPETENT OOCYTES AND COMPETENT EMBRYOS WITH HIGH POTENTIAL FOR PREGNANCY OUTCOME Inventors: Samir Hamamah (Montpellier, FR) Said Assou (Montpellier, FR) John De Vos (Montpellier, FR) Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M | |
US20160074069A1 (en) | Methods of selection of mammalian oocytes | |
Class et al. | Patent application title: METHODS OF SELECTION OF MAMMALIAN OOCYTES Inventors: Kenneth Pattrick Mcnatty (Wellington, NZ) Janet Louise Pitman (Wellington, NZ) Assignees: VICTORIA LINK LIMITED | |
Class et al. | Patent application title: METHODS AND DEVICES FOR ASSESSING RISK OF FEMALE INFERTILITY Inventors: Piraye Yurttas Beim (New York, NY, US) Assignees: Celmatix, Inc. | |
CA2863317A1 (en) | Methods of selection of mammalian oocytes | |
AU2014224108A1 (en) | Methods of selection of mammalian oocytes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/175,503 DE 05/05/2009 REIVINDICADA NO PCT/EP2010/054717, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O, ITEM 28 DO ATO NORMATIVO 128/97 E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. ESTA PERDA DEU-SE PELO FATO DO DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DE ENTRADA NA FASE NACIONAL SER DISTINTO DAQUELE QUE DEPOSITOU O PEDIDO ANTERIOR CUJA PRIORIDADE E REIVINDICADA E NAO APRESENTOU COPIA DO CORRESPONDENTE DOCUMENTO DE CESSAO DENTRO DO PRAZO LEGAL DE 60 DIAS APOS A PETICAO DE ENTRADA NA FASE NACIONAL DO BRASIL (14/12/2011) CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, ITEM 27 DO ATO NORMATIVO 128 |
|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: RETIFICACAO DA PUBLICACAO DEVIDO A INCORRECOES NO QUADRO 1 DO PARECER DE DEFERIMENTO. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2622 DE 06.04.2021, QUANTO A REDACAO DAS REIVINDICACOES - PATENTE RETIFICADA CONFORME ADI 5529, QUANTO AO PRAZO DE VIGENCIA |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2769 DE 30-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |